Overview

This trial is active, not recruiting.

Condition hiv infections
Treatment far infrared
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date February 2008
End date August 2009
Trial size 3 participants
Trial identifier NCT00574522, GAAD-HIV-CTP1

Summary

The investigators are proposing that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of killer cells to fight and destroy the human immunodeficiency virus.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Other)
Infrared Radiation, wavelength between 5 and 20 microns
far infrared
Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.

Primary Outcomes

Measure
The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 15μm wavelength) on HIV/AIDS.
time frame: One year

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - 1 Year and above Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for HIV/AIDS
Principal investigator Ken Nedd, M.D.
Description Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS or Aids) is a collection of symptoms and infections resulting from the specific damage to the immune system caused by the human immunodeficiency virus (HIV) in humans. The late stage of the condition leaves individuals prone to opportunistic infections and tumors. Although treatments for AIDS and HIV exist to slow the virus' progression, there is no known cure. The investigators are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of CD4+ T cells and other killer cells to fight and destroy the human immunodeficiency virus. The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 20μm wavelength) on HIV/AIDS.
Trial information was received from ClinicalTrials.gov and was last updated in August 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..